Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Jansen, Cynthia
VERDICT, NCT04259138 / 2019-002485-12: Determination of the Optimal Treatment Target in Ulcerative Colitis	Active, not recruiting	4	672	Europe, Canada, US, RoW	Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C	Alimentiv Inc., Takeda Development Center Americas, Inc.	Colitis, Ulcerative	03/26	03/26
VE202-002, NCT05370885 / 2021-001280-24: VE202 in Patients with Mild-to-Moderate Ulcerative Colitis	Recruiting	2	100	Europe, US, RoW	VE202, Vancomycin Oral Capsule, VE202 Placebo, Vancomycin Placebo	Vedanta Biosciences, Inc.	Ulcerative Colitis, Colitis, Ulcerative	07/25	11/25